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Abstract
Introduction: Sclerostin levels have been reported to be low in ankylosing spondylitis (AS), but there is no data
regarding the possible role of this Wnt inhibitor during anti-tumor necrosis factor (TNF) therapy. The present study
longitudinally evaluated sclerostin levels, inflammatory markers and bone mineral density (BMD) in AS patients
under anti-TNF therapy.
Methods: Thirty active AS patients were assessed at baseline, 6 and 12 months after anti-TNF therapy regarding
clinical parameters, inflammatory markers, BMD and baseline radiographic damage (mSASSS). Thirty age- and sex-
matched healthy individuals comprised the control group. Patients’ sclerostin levels, sclerostin binding low-density
lipoprotein receptor-related protein 6 (LRP6) and BMD were evaluated at the same time points and compared to
controls.
Results: At baseline, AS patients had lower sclerostin levels (60.5 ± 32.7 vs. 96.7 ± 52.9 pmol/L, P = 0.002) and
comparable sclerostin binding to LRP6 (P = 0.387) than controls. Improvement of Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis
Metrology Index (BASMI), Ankylosing Spondylitis quality of life (ASQoL) was observed at baseline vs. 6 vs.
12 months (P < 0.01). Concomitantly, a gradual increase in spine BMD (P < 0.001) and a positive correlation
between baseline mSASSS and spine BMD was found (r = 0.468, P < 0.01). Inflammatory parameters reduction was
observed comparing baseline vs. 6 vs. 12 months (P <0.01). Sclerostin levels progressively increased [baseline (60.5
± 32.7) vs. 6 months (67.1 ± 31.9) vs. 12 months (72.7 ± 32.3) pmol/L, P <0.001]. At 12 months, the sclerostin levels
remained significantly lower in patients compared to controls (72.7 ± 32.3 vs. 96.70 ± 52.85 pmol/L, P = 0.038).
Moreover, sclerostin serum levels at 12 months were lower in the 10 patients with high C reactive protein (CRP)
(≥ 5 mg/l) compared to the other 20 patients with normal CRP (P = 0.004). Of note, these 10 patients with
persistent inflammation also had lower sclerostin serum levels at baseline compared to the other patients (P =
0.023). Univariate logistic regression analysis demonstrated that AS patients with lower sclerostin serum levels had
an increased risk to have high CRP at 12 months (odds ratio = 7.43, 95% CI 1.23 to 45.01, P = 0.020) than those
with higher sclerostin values.
Conclusions: Persistent low sclerostin levels may underlie continuous inflammation in AS patients under anti-TNF
therapy.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease characterized by new bone growth
that leads to syndesmophyte formation and subsequent
vertebral ankylosis [1].
Several biomarkers, including inflammatory mediators
and factors that reflect joint tissue turnover, have been
evaluated in order to determine their relevance in AS
clinical prognosis and therapy response [2]. In this dis-
ease, the search for biomarkers that regulate bone forma-
tion is essential to understand the underlying mechanism
regulating bone growth and the inflammatory process.
Bone formation in AS has recently been associated with
upregulation of wingless (Wnt) signaling, a pathway
implicated in osteoblastogenesis [3]. Natural inhibitors of
Wnt, such as sclerostin and Dkk-1, neutralize Wnt path-
way activity and are critically important in normal bone
homeostasis, particularly osteoblastic new bone forma-
tion [3-8]. Interestingly, TNFa, an inflammatory media-
tor, is overexpressed in sacroiliac joints [9] and may also
regulate the Wnt/b catenin signaling pathway and the
Wnt proteins [10,11].
Anti-TNFa agents are efficient therapeutic options for
treating axial disease and peripheral arthritis in spondy-
loarthritis [12-16]. However, TNF-blockers do not appear
to inhibit structural damage, bone formation or radio-
graphic progression in AS patients [17-21], and a role for
inflammation particularly at sites that develop bony pro-
liferation has been suggested [5,21].
In addition, the recent observation that sclerostin is
nearly absent in AS osteocytes [5] supports the hypoth-
esis that natural inhibitors of the Wnt pathway are
relevant players in the pathogenesis of AS [3,5-8].
However, there are no data on the relevance of this
Wnt inhibitor in anti-TNF therapy response and
inflammation. In this regard, combinations of biomar-
kers reflecting an inflammatory and reparative process
is critical to clarify the scope of anti-TNFa therapeutic
benefit. We therefore assessed sclerostin serum levels,
clinical parameters, inflammatory markers and bone
mineral density (BMD) in active AS patients during
anti-TNF therapy.
Materials and methods
Subjects
Thirty consecutive active AS patients followed at the
Spondyloarthritis Outpatient Clinic and referred to the
Infusion Center were evaluated at baseline, 6 and 12
months after the initiation of anti-TNF therapy at the
standard dose; nineteen patients were taking infliximab,
nine adalimumab, and two etanercept. All of them fulfilled
the modified New York classification criteria for definite
AS [22]. Thirty sex- and age-matched healthy individuals
comprised the control group.
Inclusion criteria for patients were presence of active
disease with a Bath AS Disease Activity Index (BASDAI)
≥ 4 and/or high inflammatory parameters refractory to
nonsteroidal anti-inflammatory drugs (NSAIDs) and dis-
ease-modifying antirheumatic drugs, and referral for
anti-TNF therapy. Exclusion criteria for both groups
were other diseases that may have an effect on bone
metabolism such as hyperthyroidism, malabsorption syn-
drome, kidney and liver failure, alcohol, prior or current
use of bisphosphonates and current glucocorticoid use
(> 5 mg/day) for patients and glucocorticoid use for con-
trol group. Baseline AS treatment with NSAIDs and/or
disease-modifying antirheumatic drugs (sulfasalazine/
methotrexate) was stable for at least 3 months and
remained stable throughout the study.
Study design
Longitudinal sclerostin serum levels/binding, BMD,
inflammatory markers and clinical outcomes were evalu-
ated at baseline, 6 and 12 months after treatment. Radio-
graphic analysis in AS patients was assessed at baseline.
BMD and sclerostin measurements were also analyzed at
baseline and 12 months in the controls.
This study was approved by the Local Ethics Commit-
tee on Human Research at the University of São Paulo.
All participants gave written informed consent in accor-
dance with the Declaration of Helsinki.
Clinical Outcomes of AS
Clinical indices including BASDAI, Bath AS Functional
Index (BASFI), Bath AS Metrology Index (BASMI) and
AS quality of life questionnaire (ASQoL) were measured
at baseline and at each follow-up visit, as recommended
previously [23].
Laboratory assessment of inflammatory parameters
Inflammation was evaluated by erythrocyte sedimenta-
tion rate (ESR) in mm/h and C-reactive protein (CRP)
in mg/L. Serum matrix metalloproteinase 3 (MMP-3)
levels were measured in ng/mL using a commercially
available ELISA (human total MMP-3 immunoassay
ELISA kit, R&D Systems, Minneapolis, MN, USA),
according to the manufacturer’s recommendations.
Laboratory assessment of hormones
Hormonal determinations were performed at study entry
in AS patients and controls. Serum follicle stimulating
hormone (FSH) was analyzed in all patients and controls,
total testosterone in men and estradiol in women. All
assays were performed using the Cobas e 411 Immunoas-
say Analyzer, Roche Diagnostics GmbH (Mannheim, Ger-
many), according to the manufacturer’s instructions. The
intra- and inter-assay coefficients of variation (CVs) were
less than 6.0%.
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Laboratory evaluation of the Wnt signaling pathway
Serum samples were obtained from all patients and con-
trols after fasting and stored at -80°C until further analysis.
Serum sclerostin levels were measured by a commercial
sandwich ELISA KIT (Lot Y105, reference control: 90.5
(84 ± 25) pmol/L, Biomedica, Vienna, Austria) [24]. The
intra- and inter-assay CV was 5% and 6%, respectively.
Binding of sclerostin to the low-density lipoprotein recep-
tor-related protein 6 (LRP6) in AS patients and controls
was measured using a functional ELISA at baseline and
12 months. Briefly, microtiter plates were coated with
5 μg/mL of a chimeric human LRP6-Fc (recombinant
human LRP6-Fc chimera; R&D Systems) prior to the addi-
tion of serum samples, and detection was performed using
human anti-sclerostin biotinylated antibody (Biomedica).
The results were expressed in optical density (OD450). The
intra- and inter-assay CV for this analysis was 5% and 3 to
6%, respectively.
Radiological assessment
Radiographic images of the cervical and lumbar spine
were evaluated in AS patients concomitantly by two
trained readers (a rheumatologist and a musculoskeletal
radiologist) with agreement, using the modified Stoke
Ankylosing Spondylitis Spine Score (mSASSS) [25] at
baseline.
Bone densitometry
BMD was measured in patients and healthy controls by
dual-energy X-ray absorptiometry (DXA) using Hologic
densitometry equipment (QDR 4500 densitometer)
(Hologic Inc., Bedford, MA, USA) at the lumbar spine,
femoral neck, and total femur, at the Bone Metabolism
Laboratory of the Rheumatology Division. All BMD mea-
surements were performed by the same experienced
technologist. Precision error for BMD measurements was
determined based on standard International Society for
Clinical Densitometry (ISCD) protocols [26]. We calcu-
lated the least significant change with 95% confidence to
be 0.033 g/cm2 at the spine, 0.047 g/cm2 at the femoral
neck, and 0.039 g/cm2 at the total femur. BMD was
expressed in g/cm2.
Statistical analysis
Results are presented as mean and SD for continuous
variables and percentages for categorical variables. Data
for continuous variables were compared by the t-test to
evaluate differences between patients and controls, since
all parameters had a normal distribution. Clinical, labora-
tory and densitometric data were compared at baseline, 6
and 12 months using analysis of variance (ANOVA) with
the Huynh-Feldt correction when it was applicable, and
the Bonferroni or Frideman tests for multiple compari-
sons. The Kruskal-Wallis test was applied to compare
sclerostin serum levels at 12 months among patients with
normal CRP values (< 5 mg/L), high CRP values (≥ 5 mg/
L) and the control group. Univariate logistic regression
analysis was performed to evaluate the influence of scler-
ostin serum levels in CRP at 12 months. Differences
between categorical variables were evaluated using the
chi-squared or Fisher exact test. Spearman’s analysis was
used for correlation analysis. Statistical significance was
established at P < 0.05.
Results
Baseline demographics, disease characteristics and BMD
in patients and controls
At baseline, AS patients and the control group had a mean
age ± SD of 35.7 ± 11.0 years; 80% were men and 86.6%
were Caucasian. Patients and healthy controls had compar-
able weight (72.6 ± 13.6 vs. 75.8 ± 10.3 Kg, P = 0.313),
height (1.68 ± 0.09 vs. 1.71 ± 0.06 cm, P = 0.150) and body
mass index (BMI) (25.7 ± 4.6 vs. 25.8 ± 2.9 Kg/m2,
P = 0.909). The mean disease duration was 11.9 ± 9.3
years; one-third (33.3%) of patients had only axial involve-
ment and 66.6% of patients had axial and peripheral invol-
vement with active synovitis at study entry. Baseline
clinical assessment revealed high disease activity (BASDAI
5.11 ± 2.1, BASFI 5.4 ± 2.7, BASMI 4.06 ± 2.7) and ASQoL
score of 10.03 ± 5.2. AS patients and controls were com-
parable regarding serum FSH (6.81 ± 7.79 vs. 4.80 ±
2.81 IU/L in men, P = 0.241, and 23.32 ± 29.72 vs. 26.3 ±
48.43 IU/L in women, P = 0.900), testosterone (6.86 ± 2.57
vs. 6.72 ± 2.54 ng/mL, P = 0.841), estradiol (112.74 ±
34.15 vs. 145.96 ± 115.63 pg/mL, P = 0.515). Patients and
healthy subjects had comparable BMD at the lumbar spine
(1.032 ± 0.175 vs. 1.082 ± 0.111 g/cm2, P = 0.201), femoral
neck (0.864 ± 0.161 vs. 0.888 ± 0.135 g/cm2, P = 0.547)
and total femur (0.991 ± 0.165 vs. 1.052 ± 0.111 g/cm2,
P = 0.099).
Sclerostin serum levels and binding in patients and
controls
At baseline, AS patients had significantly lower sclerostin
levels (60.5 ± 32.7 vs. 96.7 ± 52.9 pmol/L, P = 0.002) com-
pared to healthy controls, and similar binding of sclerostin
to LRP6 (0.61 ± 0.13 vs. 0.66 ± 0.27 OD450, P = 0.387).
Also at baseline, no difference was observed in scler-
ostin levels between patients with peripheral vs. non-
peripheral involvement (69.9 ± 29.6 vs. 55.7 ± 33.9
pmol/L, P = 0.269), and patients with > 5 years versus <
5 years of disease duration (48.13 ± 33.50 vs. 65.76 ±
31.71 pmol/L, P = 0.180).
Correlation between baseline radiographic damage
(mSASSS) and lumbar spine BMD
Radiographic analyses revealed mean mSASSS of 21.1 ±
17.8 units at baseline. mSASSS at baseline correlated
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with BMD of the lumbar spine at baseline (r = 0.468,
P < 0.01) (Figure 1).
Longitudinal improvement of clinical parameters and
reduction of inflammatory parameters after anti-TNF
treatment
A significant clinical improvement was observed com-
paring baseline vs. 6 months vs. 12 months in the fol-
lowing clinical variables: BASDAI, BASFI, BASMI and
AsQoL (P < 0.01) (Table 1).
A concomitant reduction in ESR, CRP and MMP-3
levels (P < 0.001) was observed after anti-TNF therapy
comparing baseline vs. 6 months vs. 12 months (Table 1).
No difference in these inflammatory parameters was
found comparing 6 and 12 months (P > 0.05). At 12
months 10 (33.3%) patients continued to have high CRP
(≥ 5 mg/L).
Longitudinal increase in spine BMD 12 months after anti-
TNF treatment in AS patients
A significant increase in lumbar spine BMD (P < 0.001)
was found from baseline vs. 6 months vs. 12 months
after anti-TNF therapy, whereas no significant change
was observed for femoral neck and total femur BMD
(Table 1).
In the control group, no difference was observed in
lumbar spine BMD comparing baseline and 12 months
(1.082 ± 0.111 vs. 1.079 ± 0.117 g/cm2, P = 0.681).
Longitudinal evaluation of sclerostin serum levels and
binding after anti-TNF treatment
Serum levels of sclerostin gradually increased from base-
line vs. 6 months vs. 12 months after biological treatment
(60.5 ± 32.7 vs. 67.1 ± 31.9 vs. 72.7 ± 32.3 pmol/L,
P <0.001) (Table 1 and Figure 2). These levels continued
to increase between 6 and 12 months of anti-TNF ther-
apy (P = 0.024). However, at 12 months, sclerostin levels
remained significantly lower in patients compared to
controls (72.7 ± 32.3 vs. 96.70 ± 52.9 pmol/L, P = 0.038)
(Figure 2). No change was observed in binding of scleros-
tin to LRP6 at baseline and after 12 months of anti-TNF
treatment (0.61 ± 0.13 vs. 0.60 ± 0.14 OD450, P = 0.472).
In the control group no difference was detected in
sclerostin serum levels comparing baseline and 12
months (96.7 ± 52.9 vs. 99.6 ± 63.5 pmol/L, P = 0.38).
Sclerostin levels in patients with and without persistent
high CRP at 12 months
Further analysis was performed comparing patients with
persistent inflammation (CRP ≥ 5 mg/L) and those with-
out inflammation (CRP < 5 mg/L) at 12 months. Scler-
ostin serum levels at 12 months were lower in the 10
patients with high CRP compared to the other 20
patients with normal levels (50.8 ± 16.6 vs. 83.6 ± 33.0
pmol/L, P = 0.021). Reinforcing this finding, a negative
Spearman correlation between sclerostin and CRP (r =
-0.57, P = 0.001) and ESR (r = -0.59, P < 0.001) was
observed. Moreover, at 12 months, patients with normal
CRP had comparable values of sclerostin levels to the
control group (83.6 ± 33.0 vs. 96.7 ± 52.9 pmol/L, P =
0.609) while patients with persistent high CRP had signif-
icantly lower sclerostin levels than the control group
(50.8 ± 16.6 vs. 96.7 ± 52.9 pmol/L, P = 0.004) (Figure 3).
Sclerostin levels at baseline as predictor of persistent
inflammation
The association between baseline predictors of anti-TNF
response (age, disease duration, BASDAI, mSASSS,
spine BMD, CRP level, ESR level, MMP-3 and scleros-
tin) and persistent inflammation at 12 months (10
patients with CRP ≥ 5 mg/L vs. 20 patients with CRP <
5 mg/L) on univariate analysis revealed that only base-
line low sclerostin levels were significantly associated
with persistent inflammation at 12 months (41.4 ± 19.5
vs. 70.0 ± 33.3 pmol/L, P = 0.023) (Table 2). Univariate
logistic regression analysis demonstrated that AS
patients with lower sclerostin serum levels (< 65 pg/mL,
AS median time-averaged sclerostin serum levels) had
an increased risk of high CRP at 12 months (odds ratio
7.43, 95% CI 1.23 to 45.01, P = 0.020) than those with
higher sclerostin values.
Discussion
This is the first study to identify low sclerostin serum
levels as a possible marker of persistent inflammation in
AS patients under anti-TNF therapy. An important
advantage of the present study design was the exclusion
of diseases and drugs that may interfere in bone meta-
bolism since kidney failure, hyperparathyroidism [27]
and bisphosphonates [28] could regulate sclerostin
expression in osteocytes and consequently affect the
sclerostin serum levels. Also, the normal hormonal
Figure 1 Spearman’s correlation between modified Stoke
ankylosing spondylitis spinal score (mSASSS) and lumbar spine
bone mineral density (BMD).
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status of AS patients excludes the interference of this
confounding variable in our results since FSH serum
levels were recently identified as a stronger determinant
of sclerostin serum levels [29].
Sclerostin is expressed almost exclusively in bone
[30,31], specifically by osteocytes, and it is a key inhibi-
tor of osteoblast activity by binding LRP5/LRP6 and
inhibiting canonical Wnt signaling [4,32]. This Wnt sig-
naling increases bone formation by stimulating osteo-
blast proliferation and differentiation [4]. We confirmed
and extended the previous observation of a single study
that serum sclerostin is lower in AS patients compared
to healthy controls [5].
In addition, we demonstrated that TNF blockage
induces a gradual increase in the level of this inhibitor
but these levels at 12 months remained lower than
healthy individuals. This finding suggests that sclerostin
may underlie the persistent syndesmophyte bone forma-
tion reported for this disease, despite anti-TNF therapy
[17-21]. This hypothesis is reinforced by the finding of a
gradual increase in spine BMD which was correlated
with baseline mSASSS. Further longitudinal studies are
necessary to determine if sclerostin normalization is
associated with reduced long-term radiographic
progression.
Cross-talk between TNF and sclerostin appears to
occur, therefore the regulation of this Wnt inhibitor fac-
tor could be influenced by inflammation and/or resolu-
tion of this process in AS patients [33]. The persistent
low sclerostin serum levels restricted to the subgroup of
patients with continuous high inflammatory parameters
suggest that osteocyte dysfunction associated with AS
disease [5] was not reverted in these patients in spite of
TNF blockage. Moreover, baseline sclerostin levels
Table 1 Changes in clinical assessments, bone mineral density and laboratory analysis following anti-TNF treatment in
AS patients
Baseline 6 months 12 months P
BASDAI 5.11 ± 2.1 2.78 ± 2.4 2.78 ± 2.5 < 0.001
BASFI 5.40 ± 2.7 2.96 ± 2.6 2.85 ± 2.7 < 0.001
BASMI 4.06 ± 2.7 3.23 ± 2.6 3.07 ± 2.7 0.003
AsQoL, score 10.03 ± 5.2 6.43 ± 6.4 6.40 ± 6.05 0.001
ESR, mm/hr 23.75 ± 23.1 8.16 ± 15.6 7.3 ± 13.1 < 0.001
C-reactive protein, mg/dL 37.03 ± 47.9 3.35 ± 4.1 7.21 ± 20.1 < 0.001
MMP-3, ng/mL 48.6 ± 42.5 21.6 ± 22.5 23.3 ± 30.8 < 0.001
BMD lumbar spine, g/cm2 1.032 ± 0.175 1.049 ± 0.169 1.065 ± 0.169 < 0.001
BMD femoral neck, g/cm2 0.864 ± 0.160 0.865 ± 0.159 0.864 ± 0.161 0.051
BMD total femur, g/cm2 0.990 ± 0.165 0.986 ± 0.165 0.999 ± 0.171 0.981
Sclerostin, pmol/L 60.5 ± 32.7 67.1 ± 31.9 72.7 ± 32.3 < 0.001
Sclerostin binding to LRP6, OD450 0.61 ± 0.13 ND 0.60 ± 0.14 0.472
Values are expressed as mean (SD). AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology
Index; ASQoL, AS quality of life questionnaire; BMD, bone mineral density; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; LRP6, low-
density lipoprotein receptor-related protein 6; OD, optical density; ND, not done.
Figure 2 Comparisons of sclerostin serum levels in ankylosing spondylitis (AS) patients at baseline, 6 months and 12 months after
anti-TNF therapy and in healthy controls.
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seemed to be predictive of anti-TNF inflammatory
response, since AS patients with higher baseline scleros-
tin levels had a rapid inflammatory response as expected
for this treatment [12-16] and a concomitantly gradual
increase in this Wnt inhibitor.
We speculated therefore that the mechanism involved
in the syndesmophyte development is probably asso-
ciated with persistent inflammation localized in the ver-
tebral corner (cortical bone) with low sclerostin levels
and a subsequent increase of bone formation at this site
[34]. In contrast, the bone loss in the vertebra body pre-
viously reported in this disease, and not observed in the
present study, could be related to osteoclast activation,
mainly due to receptor activator of the nuclear factor
kappa-B ligand (RANKL) pathway, possibly as a result
of inflammation in the trabecular bone, or due to the
known reduced mobility and physical activity of these
patients [34,35].
The binding of sclerostin to LPR6 was comparable to
controls and was not influenced by anti-TNF treatment,
suggesting that the observed low level in patients is not
due to hampered receptor binding. In contrast, concern-
ing Dkk-1, another molecule that controls osteoblasto-
genesis, the defect of this inhibitor in AS patients seems
to be associated with the reduced affinity to LPR6 [3,6,8].
Conclusions
In conclusion, our results demonstrated that persistent
low sclerostin serum levels are associated with continu-
ous inflammation in AS patients under anti-TNF ther-
apy. Further studies are necessary to determine if this
alteration may be a marker of inflammation underlying
bone formation in AS patients during anti-TNF therapy.
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